Coronavirus (COVID-19)
Learn more
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.
Eligibility Criteria
This study is for patients age 18 and older.
Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.